spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

7th annual Orphan Drugs and Rare Diseases UK

SMI - Orphan Drugs and Rare Diseases UK

18-19 October 2017
Holiday Inn Kensington Forum, London

Orphan Drugs and Rare Diseases UK 2017: Discussing strategies for patient engagement, market access and gene therapies to enhance rare disease and orphan drug research.

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.

Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing.

Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.

Chairs for 2017:

• Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals
• Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children’s Hospital
Expert Speaker Line-Up Includes:

• Oliver Timmis, CEO, AKU Society
• Stuart Hughes, Director, Head of Pharmacology, Vertex
• Nadia Assenova, Senior Director Regulatory Affairs, EMEA, Alexion Pharma GmbH
• Christine Lavery, Group Chief Executive, MPS Society
• Hsin Loke, Director, Strategy, Operations and Finance, Rare Diseases Unit, GlaxoSmithKline
• Olaf Ritzeler, External Innovation Lead, Sanofi
• Stephen Marcus, CEO, Cantex Pharmaceuticals
• Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences

Exclusive highlights in 2017:

• Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes
• Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children
• Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement, covering improvement strategies, patient-led trials, and much more
• Gather further insight on drug approval and reimbursement with MAA, and how techniques for drug repurposing in the rare disease area can help treatment
Other event highlights include an exclusive pre-conference interactive workshop carefully selected to enhance your conference experience and encourage personal and professional development. Places are strictly limited to ensure optimal learning for attendees.

Rare Diseases Challenges and Opportunities
Tuesday 17th October 2017 | 13.30 – 17.30
Workshop Leaders: Birmingham Children’s Hospital.
phone Tel: +44 (0) 207 827 6012
email kwilliams@smi-online.co.uk
web www.orphandrugs.co.uk/samedan
email London, UK
 
Print this page
Send to a friend
   
spacer
Industry Events

Pharmapack Europe 2018

7-8 February 2018, Hall 7.1, Paris Expo, Porte de Versailles, Paris.

As Europe's dedicated Pharmaceutical Packaging and Drug Delivery event, Pharmapack is the industry's go-to place to kick-off the year.
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>


News and Press Releases

RWS expands global offering with RWS Life Sciences.

On October 1, 2017 RWS, the world's leading provider of translation, intellectual property, life sciences and language support services, announced a re-launch of its brand, website and divisional structure following a number of successful acquisitions which have significantly extended the group’s capabilities and geographical reach.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement